Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-07-29
2011-11-08
Skelding, Zachary (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007240
Reexamination Certificate
active
08053197
ABSTRACT:
The present disclosure relates to methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that increases FOXP3 expression, thereby inhibiting the autoimmune disease. Further disclosed herein are methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease.
REFERENCES:
patent: 5194425 (1993-03-01), Sharma et al.
patent: 5223426 (1993-06-01), Skibbens et al.
patent: 5569585 (1996-10-01), Goodwin et al.
patent: 5612035 (1997-03-01), Howell et al.
patent: 5614192 (1997-03-01), Vandenbark
patent: 5776459 (1998-07-01), Vandenbark
patent: 5837246 (1998-11-01), Howell et al.
patent: 5856446 (1999-01-01), Weiner et al.
patent: 5858968 (1999-01-01), Weiner et al.
patent: 5869093 (1999-02-01), Weiner et al.
patent: 5939281 (1999-08-01), Lehmann et al.
patent: 5939400 (1999-08-01), Steinman et al.
patent: 6019971 (2000-02-01), Weiner et al.
patent: 6039947 (2000-03-01), Weiner et al.
patent: 6045796 (2000-04-01), Sriram et al.
patent: 6090387 (2000-07-01), Howell et al.
patent: 6113903 (2000-09-01), Albertini et al.
patent: 6159470 (2000-12-01), Howell et al.
patent: 6197926 (2001-03-01), Gaur et al.
patent: 6207645 (2001-03-01), Howell et al.
patent: 6218132 (2001-04-01), Spack et al.
patent: 6221352 (2001-04-01), Howell et al.
patent: 6958327 (2005-10-01), Hillisch et al.
patent: 2002/0183299 (2002-12-01), Voskuhl
patent: 2003/0170648 (2003-09-01), Khattri et al.
patent: 2003/0190665 (2003-10-01), Vandenbark
patent: 2005/0032725 (2005-02-01), Rao et al.
patent: 2005/0186207 (2005-08-01), Bluestone et al.
patent: 2006/0115899 (2006-06-01), Buckner et al.
patent: 0 159 739 (1985-10-01), None
patent: 10175854 (1998-06-01), None
patent: 957359 (1999-11-01), None
patent: 101175854 (1998-06-01), None
patent: WO 94/25063 (1994-11-01), None
patent: WO 99/58977 (1999-11-01), None
patent: WO 01/32680 (2001-05-01), None
patent: WO 02/090600 (2002-11-01), None
Yagi et al., International Immunology, vol. 16, No. 11, pp. 1643-1656.
Buckner et al., Arthritis Res Ther. 2004;6(5):215-22. Epub Aug. 11, 2004.
Gronski, “Novel Insights in the Regulation of the Immune System: A Report on the FASEB Summer Research Conference on Autoimmunity,”RDS, The Review of Diabetic Studies, pp. 47-50, (Jun. 2003).
Notification of Transmittal of the International Search Report and The Written Opinion for PCT Application No. PCT/US05/26915 (dated Oct. 10, 2007).
Acha-Orbea et al., Limited Heterogeneity of Cell Receptors from Lymphocytes Mediating Autoimmune Encephalomyelitis Allows Specific Immune Intervention,Cell54:263-273 (1988).
Arden et al., “Human T-cell receptor variable gene segment families,”Immunogenetics42:455-500 (1995).
Bebo et al., “Androgens Alter the Cytokine Profile and Reduce Encephalitogenicity of Myelin-reactive T-Cells,”J. Immunol. 162:35 (1998).
Bebo et al., “Gender Differences in Experimental Autoimmune Encephalomyelitis Develop During the Induction of the Immune response to Encephalitogenic Peptides,”J. Neurosci. Res. 52:420-429 (1998).
Bourdette et al., “Basic Protein-Specific T-Cell Lines That Induce Experimental Autoimmune Encephalomyelitis in SJL/J Mice: Comparison with Lewis Rat Lines,”Cell Immunol. 112:351 (1988).
Bourdette et al., “A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis,”Multiple Sclerosis11:1-10 (2005).
Brosterhus et al., “Enrichment and detection of live antigen-specific CD4+ T cells based on cytokine secretion,”Eur. J. Immunol. 29:4053-4059 (1999).
Carlsten et al., “Additive effects of suboptimal doses of estrogen and cortisone on the suppression of T lymphocyte dependent inflammatory responses in mice,”Infamm Res. 45:26-30 (1996).
Correale et al., “Steroid Hormone Regulations of Cytokine Secretion by Proteolipid Protein-Specific CD4+ T Cells Clones Isolated from Multiple Sclerosis Patients and Normal Control Subjects,”J. Immunol. 161:3365-3374 (1998).
Choi et al., “Interaction ofStaphylococcus aureustoxin ‘superantigens’ with human T cells,”Proc. Natl. Acad. Sci. USA86:8941-8945 (1989).
Chou et al., “Immunity to TCR peptides in multiple sclerosis,”J. Immunol. 152:2520-2529 (1994).
Chou et al., “MHC-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR Vβ CDR2 peptides: comparison with myelin basic protein-specific T cells,”J. Neuroscience Res. 45:838-851 (1996).
Cochlovius et al., “In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program,”J. Immunol. 165:4731-4741 (2000).
Concannon et al., “Diversity and structure of human T-cell receptor β-chain variable region genes,”Proc. Natl. Acad. Sci. USA83:6598-6602 (1986).
Dalton et al., “Multiple Defects of Immune Cell Function in Mice with Disrupted Interferon-γ Genes,”Science259:1739-1742 (1993).
Evavold et al., “Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands,”Immunology Today14:602-609 (1993).
Fairchild, “Altered peptide ligands: prospects for immune intervention in autoimmune disease,”Eur. J. Immunogenet. 24:155-167 (1997).
Genevee et al., “An experimentally validated panel of subfamily-specific oligonucleotide primer (Vα-w29/Vβ1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction,”Eur. J. Immunol. 22:1261-1269 (1992).
Gilmore et al., “Effect of Estradiol on Cytokine Secretion by Proteolipid Protein-Specific T Cell Clones Isolated from Multiple Sclerosis Patients and Normal Control Subjects,”J. Immunol. 158:446-451 (1997).
Goverman et al., “Transgenic Mice that Express a Myelin Basic Protein-Specific T Cell Receptor Develop Spontaneous Autoimmunity,”Cell72:551-560 (1993).
Hashim et al., Antibodies Specific for VB8 Receptor Peptide Suppress Experimental Autoimmune Encephalomyelitis,J. Immunol. 144:4621-4627 (1990).
Huan et al., “Decreased FOXP3 Levels in Multiple Sclerosis Patients,”J. Neuroscience Research81:45-52 (2005).
Jansson et al., “Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice,”Journal of Neuroimmunology53:203-207 (1994).
Kimura et al., “Sequences and repertoire of the human T cell receptor α and β chain variable region genes in thymocytes,”Eur. J. Immunol. 17:375-383 (1987).
Kumar et al., “The Involvement of T Cell Receptor Peptide-specific Regulatory CD4+ T Cells in Recovery from Antigen-induced Autoimmune Disease,”J. Exp. Med. 178:909-916 (1993).
Mancia et al., “Characterization of the T-cell receptor V-β repertoire in Kawasaki disease,”Scand. J. Immunol. 48:443-449 (1998).
Martin et al., “Immunotherapy of multiple sclerosis: Where are we? Where should we go?”Nat. Immunol. 2:785-788 (2001).
Offner et al., “Vaccination with BV8S2 Protein Amplifies TCR-Specific Regulation and Protection Against Experimental Autoimmune Encephalomyelitis in TCR BV8S2 Transgenic Mice,”J. Immunol. 161:2178-2186 (1998).
Offner et al., “Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis,”Journal of Clinical Investigation105(10):1465-1472 (2000).
Olsson et al., “Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ,”J. Clin. Invest. 86:981-985 (1990).
Robinson, “The human T cell receptor β-chain gene complex contains at least 57 variable gene segments,”J. Immunol. 146:4392-4397 (1991).
Roselli et al., “Sex Differences in Androgen
Bartholomew Richard
Offner Halina
Vandenbark Arthur A.
Klarquist & Sparkman, LLP
Oregon Health & Science University
Skelding Zachary
The United States of America as represented by the Department of
LandOfFree
Methods for detecting and treating autoimmune disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for detecting and treating autoimmune disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for detecting and treating autoimmune disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4296832